Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
IQVIA Holdings Inc.
IQV
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $33.9B
$207.87
▲ +2.30%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$154.50 - $247.05
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 23.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive healthcare data platform
- Advanced predictive analytics capabilities
- Global research and consulting network
- Integrated technology and services ecosystem
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Increasing healthcare digitalization
Value
Undervalued - trading well below Life Sciences Tools peers
Momentum
Strong
+17.3% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying IQV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of $2.90 vs $2.83 consensus (+2.5% surprise). Revenue of $4.2B vs $4.1B expected (+1.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+2.5%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+2%
+2%
+5%
+5%
+10%
+8%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$3.8B
$3.9B
$4.0B
$3.8B
$4.0B
$4.1B
$4.4B
$4.2B
Margins · last 8Q
Gross
—
Operating
—
Profit
6.6%
Wall Street consensus
11 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
18%
Sell
0%
Median Price Target
$210.00
▲ +1.0% vs $207.87
Latest: Morgan Stanley · Jun 17, 2026
3 analysts covering